0001104659-24-100325.txt : 20240916 0001104659-24-100325.hdr.sgml : 20240916 20240916204604 ACCESSION NUMBER: 0001104659-24-100325 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240912 FILED AS OF DATE: 20240916 DATE AS OF CHANGE: 20240916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MOULDER LEON O JR CENTRAL INDEX KEY: 0001228865 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42270 FILM NUMBER: 241302323 MAIL ADDRESS: STREET 1: C/O TESARO, INC. STREET 2: 1000 WINTER STREET, SUITE 3300 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zenas BioPharma, Inc. CENTRAL INDEX KEY: 0001953926 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1000 WINTER ST, SUITE 1200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-271-2954 MAIL ADDRESS: STREET 1: 1000 WINTER ST, SUITE 1200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Zenas BioPharma (Cayman) Ltd DATE OF NAME CHANGE: 20221108 4 1 tm2424157-12_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-09-12 0 0001953926 Zenas BioPharma, Inc. ZBIO 0001228865 MOULDER LEON O JR C/O ZENAS BIOPHARMA, INC. 1000 WINTER STREET, SUITE 1200 WALTHAM MA 02451 1 1 0 0 Chief Executive Officer 0 Common Stock 2024-09-16 4 C 0 164523 A 164523 I See Footnote Common Stock 2024-09-16 4 C 0 108381 A 108381 D Common Stock 2024-09-16 4 C 0 372017 A 536540 I See Footnote Common Stock 2024-09-16 4 C 0 48254 A 156635 D Series Seed Convertible Preferred Stock 2024-09-16 4 C 0 1428571 D Common Stock 164523 0 I See Footnote Series A Convertible Preferred Stock 2024-09-16 4 C 0 941088 D Common Stock 108381 0 D Series B Convertible Preferred Stock 2024-09-16 4 C 0 3230268 D Common Stock 372017 0 I See Footnote Series B Convertible Preferred Stock 2024-09-16 4 C 0 418996 D Common Stock 48254 0 D Stock Option (Right to Buy) 17.00 2024-09-12 4 A 0 1486000 0 A 2034-09-11 Common Stock 1486000 1486000 D On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service. By: /s/ Chase Jayasekera, Attorney-in-Fact 2024-09-16